

and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: December 13, 2024.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2024-29977 Filed 12-17-24; 8:45 am]

**BILLING CODE 7020-02-P**

## INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701-TA-750 and 731-TA-1728 (Preliminary)]

### Sol Gel Alumina-Based Ceramic Abrasive Grains From China; Revised Schedule for the Subject Investigations

**AGENCY:** United States International Trade Commission.

**ACTION:** Notice.

**DATES:** December 13, 2024.

**FOR FURTHER INFORMATION CONTACT:** Keysha Martinez (202-205-2136), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission's TDD terminal on 202-205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202-205-2000. General information concerning the Commission may also be obtained by accessing its internet server (<https://www.usitc.gov>). The public record for these investigations may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>.

**SUPPLEMENTARY INFORMATION:** On November 25, 2024, the Commission established a schedule for the conduct of the preliminary phase of the subject investigations (89 FR 95235, December 2, 2024). Subsequently, the Department of Commerce ("Commerce") extended the deadline for its initiation determination from December 16, 2024 to January 6, 2025 (89 FR 100465, December 12, 2024). The Commission, therefore, is revising its schedule to conform with Commerce's new schedule.

The Commission must reach preliminary determinations within 25 days after the date on which the Commission receives notice from Commerce of initiation of the investigations, and the Commission's

views must be transmitted to Commerce within five business days thereafter.

For further information concerning this proceeding, see the Commission's notice cited above and the Commission's Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and B (19 CFR part 207).

**Authority:** These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.12 of the Commission's rules.

By order of the Commission.

Issued: December 13, 2024.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2024-30024 Filed 12-17-24; 8:45 am]

**BILLING CODE 7020-02-P**

## INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1427]

### Certain Components for Injection Molding Machines, and Products Containing the Same; Notice of Institution of Investigation

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on November 12, 2024, under section 337 of the Tariff Act of 1930, as amended, on behalf of Husky Injection Molding Systems LTD. of Canada and Husky Injection Molding Systems, Inc. of Milton, Vermont. Husky filed a supplemental complaint on November 29, 2024, and subsequently refiled the same "supplemental" complaint as an amended complaint on December 2, 2024. The amended complaint, alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain components for injection molding machines, and products containing the same by reason of the infringement of certain claims of U.S. Patent No. 9,713,891 ("the '891 patent"); U.S. Patent No. 11,794,375 ("the '375 patent"); U.S. Patent No. 10,093,053 ("the '053 patent"); U.S. Patent No. 8,834,149 ("the '149 patent"); and U.S. Patent No. 7,645,132 ("the '132 patent"). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainant requests that the Commission institute

an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.

**ADDRESSES:** The complaint, except for any confidential information contained therein, may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205-2000. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>.

**FOR FURTHER INFORMATION CONTACT:** Susan Orndoff, The Office of Docket Services, U.S. International Trade Commission, telephone (202) 205-1802.

#### SUPPLEMENTARY INFORMATION:

**Authority:** The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2024).

**Scope of Investigation:** Having considered the complaint, the U.S. International Trade Commission, on December 12, 2024, ordered that—

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1-2, 4, and 6-8 of the '891 patent; 1-3, 5-15, and 17-21 of the '375 patent; claims 1-4, 6, and 8-10 of the '053 patent; claims 1-9 and 18 of the '149 patent; and claims 1-4, 7, 10-12, 14-19, 21-24, and 26 of the '132 patent, and whether an industry in the United States exists as required by subsection (a)(2) of section 337;

(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the investigation, is "mold products, cavity insert products, and molding apparatus products for injection molding machines, components for injection

molding machines and products containing the same”;

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainants are:

Husky Injection Molding Systems LTD.,  
500 Queen Street South, Bolton,  
Ontario, Canada L7E 5S5

Husky Injection Molding Systems, Inc.,  
288 North Road, Milton, VT, USA,  
05468

(b) The respondent is the following entity alleged to be in violation of section 337, and is the party upon which the complaint is to be served:

NINGBO AO SHENG MOLD CO., LTD.,  
d/b/a AOSIMI, No. 8 Xingde Rd.  
Ditang Ave. YuYao, Zhejiang 315480,  
China

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

Responses to the complaint and the notice of investigation must be submitted by the named respondent in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainants of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of the respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: December 12, 2024.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2024-29906 Filed 12-17-24; 8:45 am]

**BILLING CODE 7020-02-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-1444]

#### Importer of Controlled Substances Application: Leading Pharma LLC

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Leading Pharma LLC to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before January 17, 2025. Such persons may also file a written request for a hearing on the application on or before January 17, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on September 27, 2024, Leading Pharma LLC, 3 Oak Road, Fairfield, New Jersey 07004, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Diphenoxylate ...	9170	II

The company plans to import the listed controlled substance as an importer active pharmaceutical ingredient for research and development toward manufacturing a finished dosage product for Food and Drug Administration approval. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2024-29997 Filed 12-17-24; 8:45 am]

**BILLING CODE**

## DEPARTMENT OF JUSTICE

[OMB Number 1117-0053]

### Agency Information Collection Activities; Proposed eCollection eComments Requested; Leadership Engagement Survey (LES)

**AGENCY:** Drug Enforcement Administration, Department of Justice.

**ACTION:** 30-Day notice.

**SUMMARY:** The Drug Enforcement Administration, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.

**DATES:** Comments are encouraged and will be accepted for 30 days until January 10, 2025.

**FOR FURTHER INFORMATION CONTACT:** If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please